Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Oppenheimer Maintains Outperform on Gilead Sciences, Lowers Price Target to $105

Author: Benzinga Newsdesk | February 12, 2024 08:40am
Oppenheimer analyst Hartaj Singh maintains Gilead Sciences (NASDAQ:GILD) with a Outperform and lowers the price target from $115 to $105.

Posted In: GILD

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist